Cargando…

Pharmacodynamic analysis of a fluid challenge with 4 ml kg(−1) over 10 or 20 min: a multicenter cross-over randomized clinical trial

PURPOSE: A number of studies performed in the operating room evaluated the hemodynamic effects of the fluid challenge (FC), solely considering the effect before and after the infusion. Few studies have investigated the pharmacodynamic effect of the FC on hemodynamic flow and pressure variables. We d...

Descripción completa

Detalles Bibliográficos
Autores principales: Messina, Antonio, Palandri, Chiara, De Rosa, Silvia, Danzi, Vinicio, Bonaldi, Efrem, Montagnini, Claudia, Baino, Sara, Villa, Federico, Sala, Francesca, Zito, Paola, Negri, Katerina, Della Corte, Francesco, Cammarota, Gianmaria, Saderi, Laura, Sotgiu, Giovanni, Monge García, Manuel Ignacio, Cecconi, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423602/
https://www.ncbi.nlm.nih.gov/pubmed/34494204
http://dx.doi.org/10.1007/s10877-021-00756-3
_version_ 1783749498905821184
author Messina, Antonio
Palandri, Chiara
De Rosa, Silvia
Danzi, Vinicio
Bonaldi, Efrem
Montagnini, Claudia
Baino, Sara
Villa, Federico
Sala, Francesca
Zito, Paola
Negri, Katerina
Della Corte, Francesco
Cammarota, Gianmaria
Saderi, Laura
Sotgiu, Giovanni
Monge García, Manuel Ignacio
Cecconi, Maurizio
author_facet Messina, Antonio
Palandri, Chiara
De Rosa, Silvia
Danzi, Vinicio
Bonaldi, Efrem
Montagnini, Claudia
Baino, Sara
Villa, Federico
Sala, Francesca
Zito, Paola
Negri, Katerina
Della Corte, Francesco
Cammarota, Gianmaria
Saderi, Laura
Sotgiu, Giovanni
Monge García, Manuel Ignacio
Cecconi, Maurizio
author_sort Messina, Antonio
collection PubMed
description PURPOSE: A number of studies performed in the operating room evaluated the hemodynamic effects of the fluid challenge (FC), solely considering the effect before and after the infusion. Few studies have investigated the pharmacodynamic effect of the FC on hemodynamic flow and pressure variables. We designed this trial aiming at describing the pharmacodynamic profile of two different FC infusion times, of a fixed dose of 4 ml kg(−1). METHODS: Forty-nine elective neurosurgical patients received two consecutive FCs of 4 ml kg(−1) of crystalloids in 10 (FC(10)) or 20 (FC(20)) minutes, in a random order. Fluid responsiveness was defined as stroke volume index increase ≥ 10%. We assessed the net area under the curve (AUC), the maximal percentage difference from baseline (d(max)), time when the d(max) was observed (t(max)), change from baseline at 1-min (d(1)) and 5-min (d(5)) after FC end. RESULTS: After FC(10) and FC(20,) 25 (51%) and 14 (29%) of 49 patients were classified as fluid responders (p = 0.001). With the exception of the AUCs of SAP and MAP, the AUCs of all the considered hemodynamic variables were comparable. The d(max) and the t(max) were overall comparable. In both groups, the hemodynamic effects on flow variables were dissipated within 5 min after FC end. CONCLUSIONS: The infusion time of FC administration affects fluid responsiveness, being higher for FC(10) as compared to FC(20). The effect on flow variables of either FCs fades 5 min after the end of infusion. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10877-021-00756-3.
format Online
Article
Text
id pubmed-8423602
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-84236022021-09-08 Pharmacodynamic analysis of a fluid challenge with 4 ml kg(−1) over 10 or 20 min: a multicenter cross-over randomized clinical trial Messina, Antonio Palandri, Chiara De Rosa, Silvia Danzi, Vinicio Bonaldi, Efrem Montagnini, Claudia Baino, Sara Villa, Federico Sala, Francesca Zito, Paola Negri, Katerina Della Corte, Francesco Cammarota, Gianmaria Saderi, Laura Sotgiu, Giovanni Monge García, Manuel Ignacio Cecconi, Maurizio J Clin Monit Comput Original Research PURPOSE: A number of studies performed in the operating room evaluated the hemodynamic effects of the fluid challenge (FC), solely considering the effect before and after the infusion. Few studies have investigated the pharmacodynamic effect of the FC on hemodynamic flow and pressure variables. We designed this trial aiming at describing the pharmacodynamic profile of two different FC infusion times, of a fixed dose of 4 ml kg(−1). METHODS: Forty-nine elective neurosurgical patients received two consecutive FCs of 4 ml kg(−1) of crystalloids in 10 (FC(10)) or 20 (FC(20)) minutes, in a random order. Fluid responsiveness was defined as stroke volume index increase ≥ 10%. We assessed the net area under the curve (AUC), the maximal percentage difference from baseline (d(max)), time when the d(max) was observed (t(max)), change from baseline at 1-min (d(1)) and 5-min (d(5)) after FC end. RESULTS: After FC(10) and FC(20,) 25 (51%) and 14 (29%) of 49 patients were classified as fluid responders (p = 0.001). With the exception of the AUCs of SAP and MAP, the AUCs of all the considered hemodynamic variables were comparable. The d(max) and the t(max) were overall comparable. In both groups, the hemodynamic effects on flow variables were dissipated within 5 min after FC end. CONCLUSIONS: The infusion time of FC administration affects fluid responsiveness, being higher for FC(10) as compared to FC(20). The effect on flow variables of either FCs fades 5 min after the end of infusion. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10877-021-00756-3. Springer Netherlands 2021-09-08 2022 /pmc/articles/PMC8423602/ /pubmed/34494204 http://dx.doi.org/10.1007/s10877-021-00756-3 Text en © The Author(s), under exclusive licence to Springer Nature B.V. 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Research
Messina, Antonio
Palandri, Chiara
De Rosa, Silvia
Danzi, Vinicio
Bonaldi, Efrem
Montagnini, Claudia
Baino, Sara
Villa, Federico
Sala, Francesca
Zito, Paola
Negri, Katerina
Della Corte, Francesco
Cammarota, Gianmaria
Saderi, Laura
Sotgiu, Giovanni
Monge García, Manuel Ignacio
Cecconi, Maurizio
Pharmacodynamic analysis of a fluid challenge with 4 ml kg(−1) over 10 or 20 min: a multicenter cross-over randomized clinical trial
title Pharmacodynamic analysis of a fluid challenge with 4 ml kg(−1) over 10 or 20 min: a multicenter cross-over randomized clinical trial
title_full Pharmacodynamic analysis of a fluid challenge with 4 ml kg(−1) over 10 or 20 min: a multicenter cross-over randomized clinical trial
title_fullStr Pharmacodynamic analysis of a fluid challenge with 4 ml kg(−1) over 10 or 20 min: a multicenter cross-over randomized clinical trial
title_full_unstemmed Pharmacodynamic analysis of a fluid challenge with 4 ml kg(−1) over 10 or 20 min: a multicenter cross-over randomized clinical trial
title_short Pharmacodynamic analysis of a fluid challenge with 4 ml kg(−1) over 10 or 20 min: a multicenter cross-over randomized clinical trial
title_sort pharmacodynamic analysis of a fluid challenge with 4 ml kg(−1) over 10 or 20 min: a multicenter cross-over randomized clinical trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423602/
https://www.ncbi.nlm.nih.gov/pubmed/34494204
http://dx.doi.org/10.1007/s10877-021-00756-3
work_keys_str_mv AT messinaantonio pharmacodynamicanalysisofafluidchallengewith4mlkg1over10or20minamulticentercrossoverrandomizedclinicaltrial
AT palandrichiara pharmacodynamicanalysisofafluidchallengewith4mlkg1over10or20minamulticentercrossoverrandomizedclinicaltrial
AT derosasilvia pharmacodynamicanalysisofafluidchallengewith4mlkg1over10or20minamulticentercrossoverrandomizedclinicaltrial
AT danzivinicio pharmacodynamicanalysisofafluidchallengewith4mlkg1over10or20minamulticentercrossoverrandomizedclinicaltrial
AT bonaldiefrem pharmacodynamicanalysisofafluidchallengewith4mlkg1over10or20minamulticentercrossoverrandomizedclinicaltrial
AT montagniniclaudia pharmacodynamicanalysisofafluidchallengewith4mlkg1over10or20minamulticentercrossoverrandomizedclinicaltrial
AT bainosara pharmacodynamicanalysisofafluidchallengewith4mlkg1over10or20minamulticentercrossoverrandomizedclinicaltrial
AT villafederico pharmacodynamicanalysisofafluidchallengewith4mlkg1over10or20minamulticentercrossoverrandomizedclinicaltrial
AT salafrancesca pharmacodynamicanalysisofafluidchallengewith4mlkg1over10or20minamulticentercrossoverrandomizedclinicaltrial
AT zitopaola pharmacodynamicanalysisofafluidchallengewith4mlkg1over10or20minamulticentercrossoverrandomizedclinicaltrial
AT negrikaterina pharmacodynamicanalysisofafluidchallengewith4mlkg1over10or20minamulticentercrossoverrandomizedclinicaltrial
AT dellacortefrancesco pharmacodynamicanalysisofafluidchallengewith4mlkg1over10or20minamulticentercrossoverrandomizedclinicaltrial
AT cammarotagianmaria pharmacodynamicanalysisofafluidchallengewith4mlkg1over10or20minamulticentercrossoverrandomizedclinicaltrial
AT saderilaura pharmacodynamicanalysisofafluidchallengewith4mlkg1over10or20minamulticentercrossoverrandomizedclinicaltrial
AT sotgiugiovanni pharmacodynamicanalysisofafluidchallengewith4mlkg1over10or20minamulticentercrossoverrandomizedclinicaltrial
AT mongegarciamanuelignacio pharmacodynamicanalysisofafluidchallengewith4mlkg1over10or20minamulticentercrossoverrandomizedclinicaltrial
AT cecconimaurizio pharmacodynamicanalysisofafluidchallengewith4mlkg1over10or20minamulticentercrossoverrandomizedclinicaltrial